150 related articles for article (PubMed ID: 31350645)
1. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy.
Stark AP; Ikoma N; Chiang YJ; Estrella JS; Das P; Minsky BD; Blum MM; Ajani JA; Mansfield P; Badgwell BD
Ann Surg Oncol; 2019 Oct; 26(11):3602-3610. PubMed ID: 31350645
[TBL] [Abstract][Full Text] [Related]
2. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.
Ikoma N; Estrella JS; Hofstetter W; Das P; Minsky BD; Ajani JA; Fournier KF; Mansfield P; Badgwell BD
Ann Surg Oncol; 2018 Jul; 25(7):2012-2017. PubMed ID: 29748883
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
5. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.
Mitchell KG; Ikoma N; Nelson DB; Maru DM; Erasmus JJ; Weston BR; Vaporciyan AA; Antonoff MB; Mehran RJ; Rice DC; Roth JA; Swisher SG; Sepesi B; Walsh GL; Correa AM; Das P; Blum MA; Badgwell BD; Hofstetter WL
Ann Thorac Surg; 2019 Sep; 108(3):845-851. PubMed ID: 31102632
[TBL] [Abstract][Full Text] [Related]
6. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy.
Badgwell B; Ajani J; Blum M; Ho L; Fournier K; Chiang YJ; Matamoros A; Das P; Mansfield P
Ann Surg Oncol; 2016 Jan; 23(1):156-62. PubMed ID: 26059652
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
8. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
10. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma.
Charalampakis N; Xiao L; Lin Q; Elimova E; Shimodaira Y; Harada K; Rogers JE; Mares J; Amlashi FG; Minsky BD; Das P; Hofstetter WL; Matamoros A; Sagebiel TL; Blum-Murphy MA; Lee JH; Weston B; Bhutani MS; Mansfield PF; Estrella JS; Badgwell BD; Ajani JA
Ann Surg Oncol; 2017 Aug; 24(8):2291-2301. PubMed ID: 27770339
[TBL] [Abstract][Full Text] [Related]
11. High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma.
Jomrich G; Hollenstein M; John M; Ristl R; Paireder M; Kristo I; Asari R; Schoppmann SF
Ann Surg Oncol; 2019 Apr; 26(4):976-985. PubMed ID: 30706229
[TBL] [Abstract][Full Text] [Related]
12. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.
Fields RC; Strong VE; Gönen M; Goodman KA; Rizk NP; Kelsen DP; Ilson DH; Tang LH; Brennan MF; Coit DG; Shah MA
Br J Cancer; 2011 Jun; 104(12):1840-7. PubMed ID: 21610705
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.
Sada YH; Smaglo BG; Tan JC; Tran Cao HS; Musher BL; Massarweh NN
J Natl Compr Canc Netw; 2019 Feb; 17(2):161-168. PubMed ID: 30787129
[No Abstract] [Full Text] [Related]
15. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
16. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction.
Barbour AP; Rizk NP; Gerdes H; Bains MS; Rusch VW; Brennan MF; Coit DG
J Am Coll Surg; 2007 Oct; 205(4):593-601. PubMed ID: 17903735
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
[TBL] [Abstract][Full Text] [Related]
20. The ypT category does not impact overall survival in node negative gastric cancer.
Ikoma N; Hofstetter WL; Estrella JS; Das P; Minsky BD; Fournier KF; Mansfield PF; Ajani JA; Badgwell BD
J Surg Oncol; 2018 Jun; 117(8):1721-1728. PubMed ID: 29949666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
